N'-[(1E)-1-(4-aminophenyl)ethylidene]-2-iodobenzohydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-[(1E)-1-(4-aminophenyl)ethylidene]-2-iodobenzohydrazide
• 英文别名: N-[(E)-1-(4-aminophenyl)ethylideneamino]-2-iodobenzamide
• 化学式: C₁₅H₁₄IN₃O
• 分子量: 379.2
• InChiKey: RUPREADNOZBDCY-VCHYOVAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
  申请人：Hannus Michael

  公开号：US20090324580A1

  公开（公告）日：2009-12-31

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
• USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES
  申请人：HANNUS MICHAEL

  公开号：US20120276121A1

  公开（公告）日：2012-11-01

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
• US8507546B2
  申请人：——

  公开号：US8507546B2

  公开（公告）日：2013-08-13
• [EN] METHOD FOR ENHANCING THE POTENCY OF HCV NEUTRALIZING ANTIBODIES
  申请人：EPIXIS

  公开号：WO2006103493A1

  公开（公告）日：2006-10-05

  [EN] The present invention relates to a method for selecting an HCV epitope which is not sensitive to HDL-mediated decrease of the neutralizing capacity of anti-HCV antibodies, as well as to methods for treating an HCV-infected patient or a subject who has been exposed to HCV, comprising administering to the patient a therapeutically effective amount of a compound inhibiting HCV/HDL/SR-BI interplay, or comprising reducing the plasma loads of HDL.
  [FR] La présente invention concerne un procédé permettant de sélectionner un épitope du VHC qui n'est pas sensible à une réduction, induite par la HDL, des capacités de neutralisation des anticorps anti VHC, ainsi que des procédés qui permettent de traiter un patient infecté par le VHC ou un sujet qui a été exposé au VHC, ce qui inclut également l'administration au patient d'une quantité thérapeutiquement efficace d'un composé inhibant l'interaction VHC/HDL/SR-BI, ou la diminution des charges de plasma de la HDL.